Latest news with #therapeutics
Associated Press
21 hours ago
- Business
- Associated Press
Sigma Chi International Fraternity Commits $31 Million Pledge to Huntsman Cancer Foundation to Establish the Sigma Chi Center for Advanced Therapeutics and Innovation
New Center at Huntsman Cancer Institute Aims to Fund Most Ambitious, Impactful Research to Improve Cancer Care DENVER, June 27, 2025 /PRNewswire/ -- Huntsman Cancer Foundation and Sigma Chi International Fraternity today announced a $31 million pledge to create the Sigma Chi Center for Advanced Therapeutics and Innovation at Huntsman Cancer Institute. Sigma Chi expects to meet their goal, the largest single pledge in the history of men's fraternity, within five to seven years, more than doubling the funds raised by the organization throughout their 12-year partnership with Huntsman Cancer Institute. After fulfilling an $11 million pledge in 2019, Sigma Chi then committed an additional $20 million to support women's research, treatment and prevention. The organization will complete this donation early, finalizing in Fall 2025. 'Since 2013, Sigma Chi has embraced our brother Jon Huntsman's vision of an end to cancer. Across North America, these men have worked tirelessly to raise money through grassroots events and their personal relationships, all in hopes of making the dream of becoming 'The Generation to End Cancer' a reality,' Bob Wilson, 73rd Grand Consul of Sigma Chi International Fraternity, said. 'Today, we are honored to further dedicate ourselves to such a worthy cause by more than doubling our financial commitment to establish the Sigma Chi Center for Advanced Therapeutics and Innovation.' The late Jon M. Huntsman, Sr., a Sigma Chi member honored as a 'Significant Sig' for his exemplary achievements, and his wife, Karen, founded Huntsman Cancer Institute as part of their commitment to creating better outcomes for cancer patients and, ultimately, finding a cure. It is a National Cancer Institute-designated Comprehensive Cancer Center, providing care to the largest geographic region of any institution. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center in the world. The Sigma Chi Center for Advanced Therapeutics and Innovation will fuel groundbreaking research, as well as propel new clinical trials that will lead to safer and more effective treatments, improved quality of life and potential cures for patients across North America and beyond. 'Sigma Chi brings to bear the collective power of nearly 240 undergraduate chapters across North America all coming together to raise money for Huntsman Cancer Foundation,' says Michael Delzotti, FAHP, CFRE, President and COO, Huntsman Cancer Foundation. 'This partnership is of paramount importance to cancer patients and their families who seek treatment not only at Huntsman, but also around the world, because it will drive critical breakthroughs in cancer research. Sigma Chi's rallying cry, to be 'The Generation to End Cancer,' is a powerful force for good.' Sigma Chi undergraduates across the U.S. and Canada have brought their campus communities together to raise funds for the groundbreaking research and innovation taking place at Huntsman Cancer Institute through hallmark fundraising events like Derby Days, while some have raised money throughout the school year. Sigma Chi chapters raised a recording-breaking $5 million in the 2024-2025 school year. 'Huntsman Cancer Institute is united with Sigma Chi in our ambition to end cancer as we know it,' says Mary Beckerle, PhD, CEO of Huntsman Cancer Institute. 'The Sigma Chi Center for Advanced Therapeutics and Innovation will allow us to advance the best science and new clinical trials that will materially change cancer outcomes for individuals across North America and beyond. We are so grateful to Sigma Chi for making this new commitment in our shared quest to eradicate cancer.' About Sigma Chi International Fraternity Founded in 1855, Sigma Chi International Fraternity is a men's organization dedicated to the pursuit of friendship, justice and learning. Today, there are more than 275,000 living members of Sigma Chi, including 17,000 active members at 236 campuses across North America. During its 164-year history, Sigma Chi has initiated more than 350,000 men who have been charged to live according to its seven core principles: courage, wisdom, integrity, high ambition, self-control, courtesy and fidelity. For more information, visit About Huntsman Cancer Foundation Huntsman Cancer Foundation's sole purpose is to raise funds to support the mission of Huntsman Cancer Institute: To understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients and to provide education about cancer risk, prevention and care. Huntsman Cancer Foundation is dedicated to ensuring excellence in these endeavors through the development and prudent stewardship of private resources. All HCI fundraising initiatives happen through Huntsman Cancer Foundation, which is a public, functionally integrated, Type 3 501 (c)(3). About Huntsman Cancer Institute Huntsman Cancer Institute at the University of Utah is a National Cancer Institute-designated Comprehensive Cancer Center. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to create pioneering cancer treatments beyond the standard of care today. We have more than 325 open clinical trials and 276 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient's unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman. View original content: SOURCE Sigma Chi International Fraternity
The Independent
a day ago
- Health
- The Independent
The shocking speed at which cold sore virus hijacks human DNA
A new study is the first to prove that the Herpes Simplex Virus (HSV-1) deliberately reshapes the human genome and reorganises infected cells within an hour of infection. The virus compacts and densifies human DNA to access host genes essential for its reproduction, a previously unknown mechanism of manipulation. Researchers discovered that blocking a single host cell enzyme, topoisomerase I, completely prevented the virus from rearranging the human genome and stopped infection in cell culture. This finding offers a potential new therapeutic target to control HSV-1, which affects nearly four billion people worldwide. HSV-1, while often causing benign cold sores, can lead to severe complications in rare cases and has been linked to dementia in older adults.
Yahoo
2 days ago
- Business
- Yahoo
Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On June 10, Raymond James resumed coverage of Tectonic Therapeutic, Inc. (NASDAQ:TECX) with an Outperform rating and set a $76 price target. The rating update was accompanied by a broader research note on Biotech names. A biotechnologist in a white lab coat manipulating genes in a laboratory. The analyst told investors in a research note that risk/reward skews favorably across the sector. Although companies with a higher probability of success (PoS) lead assets result in a higher conviction, the most outsized returns may be attained by highly attractive skews on less de-risked assets. Raymond James reasoned that for Tectonic Therapeutic, Inc. (NASDAQ:TECX), its lead asset, TX45, offers one of the most attractive risk-reward propositions in the biotech landscape, which is currently experiencing favorable skew and suppressed valuations. The ongoing Phase 2 by Tectonic Therapeutic, Inc. (NASDAQ:TECX) targets a high unmet need indication, favorably aligning with relaxin's multi-modal mechanism of action, according to the firm. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a clinical-stage biotechnology company that discovers and develops therapeutic proteins and antibodies modulating the activity of G protein-coupled receptors (GPCR). The company develops a proprietary technology platform called GEODe to develop and discover GPCR-targeted biologic medicines. While we acknowledge the potential of TECX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
3 days ago
- Business
- Yahoo
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
XOMA Royalty (XOMA) shares soared 9% in the last trading session to close at $26.22. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.2% loss over the past four weeks. The rise in the stock price can be attributed to the positive investor mindset regarding Xoma's extensive and growing portfolio of assets, defined as the right to receive potential future payments related to the advancement of an underlying therapeutic candidate. Last month, the company reported robust financial results for the first quarter of 2025. This drug developer is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a year-over-year change of +57.1%. Revenues are expected to be $9.43 million, down 15% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For XOMA Royalty, the consensus EPS estimate for the quarter has been revised 33.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on XOMA going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> XOMA Royalty belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Compugen (CGEN), closed the last trading session 0.6% lower at $1.63. Over the past month, CGEN has returned 13.1%. Compugen's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. Compared to the company's year-ago EPS, this represents a change of -250%. Compugen currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report XOMA Royalty Corporation (XOMA) : Free Stock Analysis Report Compugen Ltd. (CGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
4 days ago
- Health
- Globe and Mail
Kidney Transplant Rejection Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight's 'Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of kidney transplant rejection, historical and forecasted epidemiology, as well as the kidney transplant rejection therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Unlock key insights into the Kidney Transplant Rejection Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Kidney Transplant Rejection Market Size Key Takeaways from the Kidney Transplant Rejection Market Report In June 2025, Biogen announced a clinical trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR. In June 2025, Tract Therapeutics Inc. organized a Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number expected to rise by 2034. According to DelveInsight's estimates, there were approximately 27 thousand incident cases of kidney transplants across the US in 2023, with the number expected to rise by 2034. In 2023, the US reported approximately 2 thousand acute and 8 thousand chronic cases of kidney transplant rejection, with these numbers expected to increase by 2034. In 2023, among EU4 and the UK, the UK reported the highest number of living kidney transplants, with approximately 46 thousand instances, followed by France, with nearly 45 thousand cases. In contrast, Italy recorded the lowest, with around 28 thousand cases. In 2023, EU4 and the UK reported approximately 2 thousand acute and 4 thousand chronic cases of kidney transplant rejection. By 2034, these numbers are expected to increase to nearly 4 thousand acute cases and 7 thousand chronic cases. In 2023, Japan had approximately 2 thousand incident cases of kidney transplants. This number is projected to rise by 2034, growing at a CAGR of 0.7%. The leading Kidney Transplant Rejection Companies such as Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Promising Kidney Transplant Rejection Pipeline Therapies such as Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Stay ahead in the competitive landscape of the Kidney Transplant Rejection Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Kidney Transplant Rejection Treatment Market Size Kidney Transplant Rejection Epidemiology Segmentation in the 7MM Total Kidney Transplant Rejection Incident Cases Total Kidney Transplant Rejection Living Cases Kidney Transplant Rejection Type-specific Cases Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Prevalence Marketed Kidney Transplant Rejection Prophylaxis Drugs MYHIBBIN: Azurity Pharmaceuticals MYHIBBIN, developed by Azurity Pharmaceuticals, is the first ready-to-use mycophenolate mofetil (MMF) oral suspension approved for preventing organ rejection in patients aged 3 months and older who have received allogeneic kidney, heart, or liver transplants. Approved by the US FDA in May 2024, MYHIBBIN is intended for use in combination with other immunosuppressive therapies. The product works by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo guanosine nucleotide synthesis pathway, leading to the suppression of T and B lymphocyte proliferation and cytokine production, which prevents graft rejection. THYMOGLOBULIN: Sanofi THYMOGLOBULIN, developed by Sanofi, is an immunosuppressive therapy derived from rabbit serum through immunization with human thymocytes. This purified, pasteurized IgG product targets T lymphocyte antigens and is designed for the prevention of acute kidney transplant rejection. Administered via intravenous infusion, it exerts therapeutic effects by clearing circulating T cells and modulating their activation, homing, and cytotoxic functions. Its mechanism includes targeting multiple T-cell markers, such as CD2, CD3, CD4, and HLA-DR, promoting immune suppression and reducing the risk of transplant rejection. NULOJIX: Bristol Myers Squibb NULOJIX (belatacept), developed by Bristol Myers Squibb, is a selective T-cell costimulation blocker approved for the prevention of organ rejection in adult kidney transplant recipients. Administered via intravenous infusion, NULOJIX is used alongside basiliximab induction, mycophenolate mofetil, and corticosteroids. Its mechanism of action involves targeting CD80 and CD86 on antigen-presenting cells, thereby preventing CD28-mediated T-cell activation, a key driver of immunologic rejection. This results in reduced T-cell proliferation and cytokine production, including interleukin-2 and TNF-a, mitigating the immune response in transplant rejection. Emerging Kidney Transplant Rejection Drugs MDR-101: Medeor Therapeutics MDR-101, developed by Medeor Therapeutics, is an innovative cellular therapy derived from the blood and peripheral stem cells of a living kidney donor. The therapy is designed to induce donor-specific immune tolerance, effectively preventing kidney transplant rejection. By reprogramming the recipient's immune system to accept the donor organ, MDR-101 eliminates the need for lifelong immunosuppressive drugs and their associated side effects, thereby enhancing transplant kidney function and long-term survival. Positive interim data from a Phase III trial, presented as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week in November 2023, highlighted its potential as a breakthrough in transplantation medicine. MDR-101 has received ODD in both the US and EU. The clinical trial is being conducted under an FDA Special Protocol Assessment (SPA). In September 2020, the US FDA also granted Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101 for the prevention of kidney transplant rejection. Further, in January 2018, the California Institute for Regenerative Medicine (CIRM) awarded USD 18.8 million to support the Phase III clinical trial under its clinical trial funding initiative. Tegoprubart (AT-1501): Eledon Pharmaceuticals Tegoprubart, developed by Eledon Pharmaceuticals, is a humanized monoclonal antibody targeting the CD40L pathway, designed to prevent kidney transplant rejection by blocking the CD40-CD40L interaction. This innovative immunosuppressive therapy aims to replace traditional calcineurin inhibitors (CNIs), such as tacrolimus, potentially improving long-term graft survival and patient outcomes. In September 2024, Eledon completed enrollment for the Phase II BESTOW trial, four months ahead of schedule, with topline results anticipated in Q4 2025. Phase Ib trial data presented at the American Transplant Congress (ATC) in June 2024 demonstrated the drug's safety and tolerability. Riliprubart (BIVV020, SAR445088): Sanofi Riliprubart, developed by Sanofi, is an IgG4 humanized monoclonal antibody under investigation for the treatment of Antibody-Mediated Rejection (AMR) in kidney transplants. The drug works by selectively inhibiting activated complement component C1s, a critical mediator of the inflammatory processes associated with AMR. Phase II clinical trials are currently underway to evaluate the efficacy and safety of Riliprubart in patients diagnosed with or at risk of AMR. Administered intravenously, Riliprubart represents a promising therapeutic approach to addressing AMR in kidney transplant recipients. Discover the future of Kidney Transplant Rejection Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Kidney Transplant Rejection Market Drivers and Barriers Kidney Transplant Rejection Market Outlook Kidney transplant rejection is a major concern for recipients, as it can severely affect the long-term success and function of the transplanted organ. Rejection happens when the recipient's immune system recognizes the donor kidney as foreign, prompting an immune response that damages the graft. There are two main types of rejection: Acute, which usually occurs within the first-year after transplantation, and chronic, which develops gradually over several years and is more prevalent. Chronic rejection is often associated with insufficient immunosuppression or non-compliance with medication regimens, leading to ongoing immune attacks that result in scarring and eventual loss of kidney function. Around 15–20% of transplant recipients experience some form of rejection, highlighting the importance of regular monitoring and strict adherence to immunosuppressive therapy to reduce this risk. Kidney Transplant Rejection Drugs Market Insights Currently, a variety of medication approaches for kidney transplant rejection prophylaxis involve approved treatments that utilize different mechanisms of action to support long-term transplant success. These include ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT, among others, all of which play a crucial role in managing immune responses and minimizing the risk of rejection. Kidney transplant rejection aims to manage immune responses, prevent further organ damage, and ensure long-term transplant success. Treatment involves a combination of immunosuppressive therapies, close monitoring, and supportive care to address acute and chronic rejection. Key goals include preserving graft function, reducing inflammation, minimizing complications, and improving the patient's quality of life. Lifestyle adjustments, including dietary management and adherence to medication regimens, are essential for long-term success. While challenges remain, ongoing research is focused on advancing therapies to enhance graft survival and improve outcomes for transplant recipients. Explore the dynamics of the Kidney Transplant Rejection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Kidney Transplant Rejection Ongoing Clinical Trials Analysis Scope of the Kidney Transplant Rejection Market Report Coverage- 7MM Study Period- 2020-2034 Kidney Transplant Rejection Companies- Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Kidney Transplant Rejection Pipeline Therapies- Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection Current Marketed and Kidney Transplant Rejection Emerging Therapies Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers Kidney Transplant Rejection Unmet Needs, KOL's views, Analyst's views, Kidney Transplant Rejection Market Access and Reimbursement Table of Contents 1. Key Insights 2. Report Introduction 3. Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Disease Background and Overview 7. Methodology 8. Epidemiology and Patient Population 9. Patient Journey 10. Marketed Drugs 11. Emerging Drugs 12. Kidney Transplant Rejection – 7MM Market Analysis 13. KOL Views 14. Unmet Needs 15. SWOT Analysis 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
